Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of “Hold” from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been given an average rating of “Hold” by the five brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $8.10.

Several research analysts have weighed in on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Morgan Stanley boosted their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th.

Key Recursion Pharmaceuticals News

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Genentech collaboration advanced: Genentech moved the collaboration’s first neuroscience target into a joint early-discovery program. The milestone provides early validation that Recursion’s AI-enabled platform can identify novel, biologically supported drug targets. Recursion Reports Second Quarter Financial Results
• Positive Sentiment: Pipeline milestones remain on track: REC-7735 received IND clearance, with its Phase 1/2 ZINNIA trial for selected PIK3CA H1047R-mutant solid tumors expected to begin in the second half of 2026. The company also plans to present additional Phase 2 data for REC-4881 in familial adenomatous polyposis in November. Recursion Outlines 2026 Cash Operating Expense Guidance
• Neutral Sentiment: Spending outlook was reduced: Recursion outlined approximately $375 million in 2026 cash operating expenses, which could extend its cash runway, although the company remains heavily dependent on future clinical and partnership success rather than current product revenue. Recursion Outlines 2026 Cash Operating Expense Guidance
• Negative Sentiment: Q2 results missed expectations: The company reported a $0.25 per-share loss versus the roughly $0.23–$0.24 consensus estimate. Revenue fell to $7.67 million from $19.22 million a year earlier and was well below the approximately $10.97 million analyst estimate. Despite a narrower loss than last year, the revenue miss reinforces concerns about RXRX’s current valuation and ongoing operating losses. Recursion Pharmaceuticals Reports Q2 Loss
• Negative Sentiment: Valuation remains a concern: Commentary following the results characterized RXRX as expensive relative to its still-unprofitable business and long-term share-price decline. The mixed earnings update therefore offered limited fundamental support despite positive development news. Recursion Pharmaceuticals Stock Still Looks Expensive

Insider Buying and Selling

In other news, Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the sale, the director directly owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. The trade was a 0.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares in the company, valued at $7,789,349.68. This represents a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 101,937 shares of company stock worth $381,374. 6.65% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Recursion Pharmaceuticals by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after purchasing an additional 7,407,606 shares during the period. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 11.2% in the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after purchasing an additional 3,771,357 shares in the last quarter. State Street Corp increased its stake in Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after buying an additional 7,064,963 shares during the period. Geode Capital Management LLC increased its stake in Recursion Pharmaceuticals by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock worth $44,731,000 after buying an additional 1,310,695 shares during the period. Finally, Norges Bank acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $23,473,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock opened at $3.17 on Thursday. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $7.18. The business’s fifty day simple moving average is $3.33 and its 200-day simple moving average is $3.47. The firm has a market cap of $1.68 billion, a PE ratio of -2.64 and a beta of 1.03. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The business had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.During the same period in the previous year, the business posted ($0.41) earnings per share. Equities analysts forecast that Recursion Pharmaceuticals will post -0.9 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.